About This Event
With 2 CAR-T therapies striving for global approval, and a 3rd contender from Bristol-Myers Squibb closing in on the finish line of the race to market, the CAR-TCR field continues to boom with excitement as the competition begins to heat back up.
It is well known that the current approved therapies have encountered some difficulties, specifically around their pricing and uptake in hospitals due to expensive manufacturing processes. Lots of work needs to be done in this space to reduce cost of goods and improve turnaround time to decrease the overall price of these therapies, improving their accessibility for patients globally.
These challenges in turn push the need for ground-breaking work in this space, from discovery through to commercialization, which is what the CAR-TCR Summit promises to showcase this September.